BARCLAYS PLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 51 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$1,950,000
+1641.1%
2,629,000
+1805.1%
0.00%
Q1 2020$112,000
-86.1%
138,000
-85.3%
0.00%
-100.0%
Q3 2019$805,000
+509.8%
936,000
+532.4%
0.00%
Q2 2019$132,000
+2100.0%
148,000
+2014.3%
0.00%
Q4 2018$6,000
-97.3%
7,000
-97.6%
0.00%
Q3 2017$226,000293,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders